echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > AJG: Comparison of the efficacy of biologics for endoscopic healing of the ileum and colon in patients with Crohn's disease

    AJG: Comparison of the efficacy of biologics for endoscopic healing of the ileum and colon in patients with Crohn's disease

    • Last Update: 2022-08-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Crohn's disease (CD) is an inflammatory bowel disease (IBD) characterized by transmural inflammation in any area of ​​the gastrointestinal trac.


    This trial pooled analysis of 299 CD patients from 4 clinical trial.


    Adalimumab (17/61 [29%], [OR]: 79, 95% [CI]: 77–195, P= 004) and infliximab (39/141 [27%], aOR: 59, 95% CI: 48–122, P = 008) had a higher incidence of EH at 1 yea.


    This study initially demonstrated that TNF-α antagonists (adalimumab and infliximab) were generally superior to vedolizumab and ustekinumab in achieving 1-year EH in patients with moderate-to-severe C.


    Original source:

    Narula, Neera.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.